Tirzepatide in Temple Terrace

Tirzepatide activates GIP and GLP-1 receptors; semaglutide activates GLP-1 receptors. Treatment selection still depends on the exact product, medical history, risks, response and alternatives. A mechanism or branded-drug trial result does not establish the performance of a compounded preparation.

Not automatically. Take tirzepatide and change your dose only as directed by your clinician, based on the exact product, your response and tolerability. The pricing table is not a dosing schedule. The 2.5 mg dose is a starting dose in approved Zepbound labeling, not an approved maintenance dose.

Approved tirzepatide carries a boxed warning about thyroid C-cell tumors: these occurred in rats, and the relevance to humans is unknown. Zepbound is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), or a serious allergy to its ingredients. It is not recommended with severe gastroparesis. Discuss previous pancreatitis, other gastrointestinal disease, gallbladder disease, kidney problems, diabetes medicines and low-blood-sugar risk, pregnancy, breastfeeding and other medicines before treatment. Weight-loss treatment is not appropriate during pregnancy. This is not an exhaustive safety review; your clinician assesses eligibility.

Nausea, diarrhea, vomiting and constipation are common with approved tirzepatide. Symptoms can be severe or persistent; contact the prescriber rather than assuming they will resolve. Severe or persistent abdominal pain, repeated vomiting, inability to maintain hydration or allergic symptoms require medical assessment. Breathing difficulty or swelling of the face or throat requires emergency care. Side effects are not guaranteed to disappear during dose adjustment.

Yes. The Zepbound label advises switching to a non-oral contraceptive or adding a barrier method for four weeks after starting and for four weeks after each dose increase. Discuss contraception and pregnancy plans with the prescriber before treatment.

Your clinician decides whether a switch is appropriate and gives you product-specific instructions for timing and dosing. Do not combine the medicines or use a dose conversion on your own. Approved Zepbound labeling does not recommend combining it with another tirzepatide product or a GLP-1 receptor agonist.

Weight regain can occur after treatment stops. In SURMOUNT-4, participants switched from tirzepatide to placebo regained weight, while continued treatment supported maintenance. This study does not establish outcomes for compounded products. Discuss maintenance, nutrition and follow-up with your clinician before changing your plan.

Changes in glucose control or other health measures need to be interpreted alongside your medical history and prescribed treatment. Your clinician determines appropriate follow-up and any clinically necessary testing. A compounded preparation should not be assumed to reproduce branded-drug trial outcomes.

Many adult weight-management medicines are considered for a BMI of 30 or higher, or 27 or higher with a weight-related health condition. These thresholds do not guarantee eligibility. Your clinician reviews your medical history, other treatments, pregnancy plans and the specific proposed medicine before prescribing.

Labs are not routinely required for everyone. Your clinician orders testing only when it is clinically necessary, based on your history and assessment.

Yes. Care can be completed by telemedicine, or you can visit Altera Wellness in Temple Terrace for appointments and weigh-ins. Follow-up is based on clinical needs.

Yes. Shipping to your doorstep is included in the stated price when medication is prescribed.

The $99 first month is for eligible new patients starting tirzepatide at 2.5 mg, if prescribed after consultation. Ongoing pricing is $199 per calendar month at 2.5–7.5 mg or $299 at 10 mg and above. Semaglutide remains $199 per month for all doses.

Membership renews monthly until canceled. Tirzepatide billing recurs by calendar month at the price for your prescribed dose. The eligible $99 first month is followed by the applicable ongoing rate. Contact our team for cancellation details.

No. Compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before marketing. FDA advises their use only when a patient’s medical needs cannot be met by an approved drug. Ask which exact product is proposed, why it is appropriate and what approved alternatives are available. Evidence from branded-drug trials does not establish outcomes for a compounded preparation.